I'm LongbridgeAI, I can summarize articles.SHYNDEC released its semi-annual performance report for 2025, stating that the total operating revenue during the reporting period was 4.878 billion yuan, a year-on-year decrease of 18.16%; the net profit attributable to the parent company was 672 million yuan, a year-on-year decrease of 6.46%. The net profit after deducting non-recurring gains and losses was 637 million yuan, a year-on-year decrease of 6.72%. The basic earnings per share were 0.5011 yuan. Affected by market supply and demand, the sales volume and prices of some penicillin raw materials and intermediates decreased, and the sales revenue of the formulation business also declined due to centralized procurement and reduced demand
According to the Zhitong Finance APP, SHYNDEC (600420.SH) disclosed its semi-annual performance report for 2025. The company's total operating revenue in the first half of the year was 4.878 billion yuan, a year-on-year decrease of 18.16%; the net profit attributable to shareholders of the listed company was 672 million yuan, a year-on-year decrease of 6.46%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 637 million yuan, a year-on-year decrease of 6.72%. The basic earnings per share were 0.5011 yuan.
During the reporting period, affected by market supply and demand, the sales volume and prices of some penicillin raw materials and intermediates decreased year-on-year; in the formulation business segment, the sales revenue of some cephalosporin, hormone, and neurological products decreased year-on-year due to factors such as centralized drug procurement and reduced terminal demand